Engelstein Erica D
Cardiac Electrophysiology Section, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.
Am J Cardiol. 2003 May 8;91(9A):62F-73F. doi: 10.1016/s0002-9149(02)03340-4.
Sudden cardiac death is responsible for >40% of patients with heart failure losing their lives. Thus, the prevention of life-threatening cardiac arrhythmias is a major goal in the management of heart failure. In several randomized clinical trials, electrical therapy with the implantable cardioverter defibrillator (ICD) has proved superior to medical antiarrhythmic therapy in both the secondary and primary prevention of sudden cardiac death in patients with reduced left ventricular function. In addition to the severity of left ventricular dysfunction, the etiology of the cardiomyopathy appears to be a determinant in the benefit derived from this form of electrical therapy. Whereas patients with ischemic cardiomyopathy clearly show improved survival with ICD therapy, outcome data in patients with nonischemic cardiomyopathy are less convincing. The major challenge lies in the risk stratification of patients with heart failure for arrhythmic death. Catheter ablation is another form of electrical therapy that can help in the treatment of patients with heart failure. In patients with a tachycardia-mediated cardiomyopathy because of drug-refractory atrial fibrillation with rapid ventricular response, catheter ablation of the atrioventricular node and pacemaker implantation can effectively restore a physiologic heart rate, often with dramatic regression of left ventricular dysfunction. In patients with frequent ICD therapies because of frequent recurrences of ventricular tachyarrhythmias, catheter ablation of ventricular tachycardia can be an effective adjunctive therapy. New catheter ablation techniques and new atrial pacing algorithms can also significantly reduce the atrial fibrillation burden in patients with heart failure who are particularly susceptible to decompensation because of atrial fibrillation. Pacing for hemodynamic benefit in heart failure has evolved from dual-chamber pacing modes with optimized atrioventricular delay to biventricular pacing resulting in cardiac resynchronization. This new treatment modality for advanced heart failure has been shown to result in significant symptomatic and hemodynamic improvement.
心脏性猝死导致超过40%的心力衰竭患者死亡。因此,预防危及生命的心律失常是心力衰竭管理的主要目标。在多项随机临床试验中,对于左心室功能降低的患者,植入式心脏复律除颤器(ICD)进行的电疗法在心脏性猝死的二级和一级预防中均已证明优于药物抗心律失常疗法。除了左心室功能障碍的严重程度外,心肌病的病因似乎也是这种电疗法获益的一个决定因素。虽然缺血性心肌病患者接受ICD治疗后生存率明显提高,但非缺血性心肌病患者的预后数据则不那么令人信服。主要挑战在于对心力衰竭患者心律失常死亡的风险分层。导管消融是另一种电疗法,可帮助治疗心力衰竭患者。对于因药物难治性心房颤动伴快速心室反应而导致心动过速介导的心肌病患者,房室结导管消融和起搏器植入可有效恢复生理心率,左心室功能障碍通常会显著消退。对于因室性快速性心律失常频繁复发而接受频繁ICD治疗的患者,室性心动过速导管消融可以是一种有效的辅助治疗。新的导管消融技术和新的心房起搏算法也可显著减轻心力衰竭患者的心房颤动负担,这些患者因心房颤动特别容易出现失代偿。心力衰竭中为获得血流动力学益处而进行的起搏已从具有优化房室延迟的双腔起搏模式发展到导致心脏再同步的双心室起搏。这种用于晚期心力衰竭的新治疗方式已被证明可显著改善症状和血流动力学。